Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Pfizer

Biopharma revenues were $9.8 billion, up 6% operationally, primarily driven by Vyndaqel.

By: Contract Pharma

Contract Pharma Staff

Pfizer

2Q Revenues: $11.8 billion (-11%)

2Q Earnings: $3.4 billion (-32%)  

YTD Revenues: $23.8 billion (-10%)

YTD Earnings: $6.8 billion (-24%)

Comments: Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan. Acquisitions and other business development activities completed in 2019 and in the first half of 2020 impacted financial results. Revenues in the quarter included an estimated unfavorable impact of approximately $500 million, or 4%, due to COVID-19, partially offset by increased U.S. demand for certain sterile injectable products and increased adult demand for Prevenar 13 in certain international markets.

Biopharma revenues were $9.8 billion, up 6% operationally, primarily driven by Vyndaqel/Vyndamax global revenues of $277 million. Global Eliquis sales were up 19% operationally, primarily driven by continued increased adoption. Ibrance sales in the U.S. were up 11%, primarily driven by increased cyclin-dependent kinase (CDK) class penetration and CDK market share in metastatic breast cancer. International Prevenar 13 sales were up 18% operationally, while sales in the U.S. were down 22% due to unfavorable impact of disruptions to wellness visits due to COVID-19. Inlyta in the U.S. was up 120%, primarily reflecting increased demand. Xtandi sales in the U.S. were up 32%, primarily driven by continued strong demand. International Enbrel sales were down 16% operationally, due to biosimilar competition. Chantix sales in the U.S. were down 21%, due to lower demand resulting from reduced doctor visits. Upjohn revenues totaled $2.0 billion, down 31% operationally, due to significant declines for Lyrica in the U.S. due to multi-source generic competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters